Evaluation of Treatment Pathways in Oncology: An Example in mcrpc



Similar documents
Evaluation of Treatment Pathways in Oncology: Modeling Approaches. Feng Pan, PhD United BioSource Corporation Bethesda, MD

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Kanıt: Klinik çalışmalarda ZYTIGA

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG study results presented at ASCO 2004

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015.

What s new in prostate cancer research? Highlights of GU-ASCO 2014

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S

First-line Hormone Therapy

Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Traitement médical du Cancer de la Prostate: du désert à la profusion. Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

7. Prostate cancer in PSA relapse

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Guidance for Industry

Background. t 1/2 of days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Department of Clinical Effectiveness V10 Approved by the Executive Committee of the Medical Staff 10/28/2014

Prostate Cancer. Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Activity of pemetrexed in thoracic malignancies

Prostate Cancer Studies

Current management of advanced and castration resistant prostate cancer Leonard G. Gomella, MD, 1 Daniel P. Petrylak, MD, 2 Bobby Shayegan, MD 3 1

Recommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Prior Authorization Guideline

Corporate Medical Policy

2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL. Howard R. Soule, PhD

NCCN Prostate Cancer Early Detection Guideline

一 本 共 識 依 下 列 參 考 資 料 修 改 版 本 : 1. NCCN Clinical Practice Guidelines in Oncology- Prostate cancer V

Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Come è cambiata la storia naturale della malattia

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Prostate Cancer Treatment: What s Best for You?

Cytotoxic Therapy in Metastatic Breast Cancer

the standard of care /1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Brussels, March 7, 2009

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Introduction Objective Methods Results Conclusion

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

Prior Authorization Guideline

Avastin in Metastatic Breast Cancer

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Guidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Ching-Yao Yang, Yu-Wen Tien

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

How valuable is a cancer therapy? It depends on who you ask.

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Advances in Prostate Cancer (Localized to Newly metastatic) Christopher Sweeney, MBBS Dana Farber Cancer Institute

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

Treatment of metastatic prostate cancer CLARE GILSON, THUBEENA MANICKAVASAGAR AND SIMON CHOWDHURY

METASTATIC PROSTATE CANCER

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer

Scottish Medicines Consortium

Historical Basis for Concern

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

The PSA Controversy: Defining It, Discussing It, and Coping With It

Advanced prostate cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline. Prostate Cancer. Version NCCN.org. Continue

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)

Transcription:

Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Sonja Sorensen, MPH United BioSource Corporation Bethesda, MD 1 Objectives Illustrate selection of modeling approach for evaluating pathways in mcrpc. Review data needs for developing and evaluating pathways. 2 1

Brief Overview of mcrpc Prostate cancer is most common non-skin cancer among men in the US. 241,740 new cases of prostate cancer and 28,170 prostate cancerrelated deaths were estimated for 2012. 1 Estimated expenditures approached $11.9 billion,* making it the fifth most costly cancer. 2 Disease course Typically slow disease course, and only a small percentage of patients eventually progress to metastatic phase. 3 Nearly all metastatic prostate cancer ultimately becomes castrationresistant. mcrpc is defined as disease progression with rising serum prostate-specific antigen (PSA) levels despite surgical or medical castration. This stage typically begins as asymptomatic or mildly symptomatic disease; progression is associated with increasing symptoms and pain. Median survival times reported from historical studies was <1 yr 4, but is now vastly improved, averaging 18 24 months or more. 3 *In 2012 dollars Sources: 1 American Cancer Society. Cancer Facts & Figures 2010; 2 National Cancer Institute. Cancer Trends Progress Report 2009/2010 Update. 2010; 3 Solo et al. 2011; 4 Eisenberger et al. 1985. 2010 Treatment Recommendations in mcrpc 4 2

Clinical States in mcrpc Post docetaxel Symptomatic/ rapid progression Asymptomatic/ minimally symptomatic 2013 Treatment Recommendations in mcrpc NCCN guidelines show the options are quickly increasing for the clinical states of mcrpc (asymptomatic/minimally symptomatic, symptomatic/rapid progression, and post-docetaxel). 5 Symptomatic Yes No Docetaxel (category 1) Mitoxantrone Abiraterone acetate Enzalutamide Palliative RT or radionucleide for symptomatic bone metastases Clinical trial Sipuleucel-T (category 1) Secondary hormone therapy Antiandrogen Antiandrogen withdrawal Abiraterone acetate (category 1) Enzalutamide Ketoconazole Steroids DES or other estrogen Docetaxel Clinical trial Abiraterone acetate j or enzalutamide (category 1, post-docetaxel) Cabazitaxel (category 1, post-docetaxel) Salvage chemotherapy Docetaxel rechallenge Mitoxantrone Other secondary hormone therapy Antiandrogen Antiandrogen withdrawal Ketoconazole Steroids DES or other estrogen Sipuleucel-T Clinical trial Highlighting indicates s recently added. Category 1: Based upon high-level evidence, there is uniform consensus that the intervention is appropriate. Source: NCCN. NCCN Guidelines version 2.2013 Prostate Cancer. 2013; http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 8 May 2013. Recently Approved Treatments A number of drugs have been recently approved in the US, each with a survival benefit versus the control, but at a higher drug cost FDA Approval Efficacy Toxicity Median Tx Duration (Months) AWP/ASP Drug Cost/Month Sipuleucel-T 2010 4.1 to 4.5 months (HR 0.76, 0.59) Mild 3 doses at ~ 2- weeks $70,842* Abiraterone 2012 (expanded indication) 5.2 months (HR 0.792) Mild 13.8 (daily dosing) $7,080 Docetaxel 2004 2.4 months (HR 0.761) Hematologic (neutropenia) 6.6 (every 3 weeks) $1,547* Cabazitaxel 2010 2.4 months (HR 0.70) Hematologic (neutropenia) 4.1 (6 cycles) $11,793* Abiraterone 2010 3.9 to 4.6 months (HR 0.65-0.74) Enzalutamide 2012 4.8 months (HR 0.63) Mild 8 (daily dosing) $7,080 Mild 8.3(daily dosing) $7,886 Source: Drug prescribing information; Thomson Reuters. RED BOOK Online. Micromedex; 2012. Available at: http://www.redbook.com/redbook/. Accessed December, 2012; cost for Sipuleucel-T accessed May 2013. *ASP 3

Rationale for Treatment Pathway Modeling Given the rapid emergence of several options, the clinical question is how to best sequence these agents to optimize clinical and cost outcomes. Models are a framework that allow the synthesis of evidence from numerous sources and can be used to pull together inform clinical and cost implications as evidence becomes available. Other approaches to evaluating pathways have important limitations in mcrpc: Clinical trials data alone only provide limited data on efficacy, and current mcrpc trials are not designed to explore sequences. Database studies require data, but many of the relevant mcrpc s are only recently approved. Providing earlier evidence of the costs and outcomes associated with clinical pathways may help with decision making. Considerations For Selecting Model Approach in mcrpc Modeling Objective Events of Interest/ Outcome Measures Subsequent Treatments Compare pathway options over the course of mcrpc to reflect the new paradigm. Time on, time to disease progression, OS mcrpc trials have shown that benefits and survival differs by ECOG, number of previous therapies, level of pain, and presence of visceral disease. Subsequent s along the mcrpc spectrum have been shown to significantly prolong survival. Subsequent options may depend on previous s and patient characteristics, such as comorbidities, previous toxicities, and age. Heterogeneity of Patients Number of subgroups (age, comorbidities, PSA levels) 8 These considerations point to the use of a DES/individual time-to-event simulation. Captures multiple courses of disease, can adjust OS benefit based on the drugs received, allows for testing different scenarios that were not observed in the trial, and can capture impacts of patient heterogeneity. 4

Modeling Steps Develop Model Framework To capture benefits, the model needs to simulate individual clinical experiences, starting from first through subsequent s until death. Example pathways using newly available drugs: Asymptomatic/ minimally symptomatic Sipuleucel or Abiraterone Symptomatic/Rapid progression Docetaxel Post-docetaxel Cabazitaxel or Abiraterone or enzaluatmide BSC BSC BSC 9 BSC: best supportive care Steps for DES using Example Pathway Patient characteristics and disease status (ECOG status over time, PSA progression, or radiographic progression or opiate use at time of discontinuation) Patients enter simulation Assign baseline profile Clone patients Start 1 st line e.g. sipuleucel-t or abiraterone end/pfs Update status, risk and time to next event Equation predicting time-to-event (discontinuation from 1 st line, start of next therapy, death etc.) Parameter Coefficient Patient Characteristics Intercept Tx Age ECOG score Scale 2.5 0.5 0.04 0.12 0.8 Yes = 1 65 1 Adjust intercept Event times (T i ) explained by survival curves that follow a parametric distribution (e.g., Weibull) Sample a random number (RND) UNIF(0,1) and compute time corresponding to the RND on the curve Start next therapy e.g. docetaxel Start post docetaxel end/pfs end/pfs Update status, risk and time to next event Update status, risk and time to next event 5

Data Needed for Treatment Pathway Models Asymptomatic/ minimally symptomatic e.g., sipuleucel-t or abiraterone Symptomatic/Rapid progression e.g., docetaxel Post-docetaxel e.g., abazitaxel or abiraterone or enzalutamide Effectiveness Inputs Time to first-line end/progression Time to death (without next-line tx) Incidence of toxicities Effectiveness Inputs Time to second-line end/ progression Time to death (without next-line tx) Incidence of toxicities Effectiveness Inputs Time to third-line end/progression Time to death Incidence of toxicities Utilities On-/PFS Disutility from toxicities Costs Administration costs Drug costs Toxicities Medical follow-up Symptom management Utilities On-/PFS Disutility from toxicities Costs Administration costs Drug costs Toxicities Medical follow-up Symptom management Utilities On-/PFS Disutility from toxicities Post-progression Costs Administration costs Drug costs Toxicities Medical follow-up Symptom management 11 Summary In mcrpc, the landscape has been quickly changing. With many more options available along the mcrpc disease spectrum, the relevant question for decision makers is identifying the optimal pathways in terms of health outcomes and costs. An individual simulation modeling approach can better capture the multiple courses of therapy, apply impacts of drugs to quality of life and survival outcomes, and assign costs. It can also evaluate pathways early on, before full implementation of the pathways. It can capture the important heterogeneity of the mcrpc population in terms of predictors of survival and benefit (e.g., ECOG, level of pain, number of previous therapies received). However, this modeling approach requires individual-level data from at least some trials to inform the prediction equations. 12 6